Related Experiment Video
Updated: Sep 1, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.7K
New and Emerging Therapies for Dyslipidemia
Alberto Zambon1, Maurizio Averna2, Laura D'Erasmo3
1University of Padova, Clinica Medica 1, Department of Medicine - DIMED, Via Giustiniani 2, Padova 35128, Italy.
Endocrinology and Metabolism Clinics of North America
|August 13, 2022
Summary
New lipid-lowering drugs, informed by genetic research, offer promising strategies to manage atherosclerotic cardiovascular disease (ASCVD) risk. These advancements aim to improve outcomes for high-risk patients, including those with type 2 diabetes.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Pharmacology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) poses a significant global health burden.
- Current treatments (antihypertensives, statins, antiplatelets) are insufficient for many high-risk patients, particularly those with established ASCVD or type 2 diabetes.
- Despite optimal therapy, cardiovascular events persist in these populations.
Purpose of the Study:
- To review novel lipid-lowering therapies.
- To discuss their mechanisms of action, impact on lipid parameters, and safety profiles.
- To highlight emerging treatments for clinical practice.
Main Methods:
- Review of recent developments in lipid and atherosclerosis research.
- Focus on lipid-lowering approaches supported by human genetic evidence.
- Analysis of mechanisms, lipid effects, and safety.
Main Results:
- Several new lipid-lowering drugs are nearing clinical availability.
- These agents are based on robust scientific understanding, including genetic insights.
- They offer potential for improved lipid management and cardiovascular risk reduction.
Conclusions:
- Emerging lipid-lowering therapies represent a significant advancement in managing ASCVD.
- Genetic evidence has been crucial in developing these novel approaches.
- These new treatments are expected to enhance clinical practice for high-risk cardiovascular patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
847
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847
01:26Atherosclerosis III: Management
30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
01:27Peripheral Artery Disease III: Interprofessional Care
28
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
28
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
248
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
248
01:24Lipid Absorption
639
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
639
01:24Overview of Lipid Metabolism
2.2K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.2K